Plus Therapeutics Q3 net loss widens Y/Y
seekingalpha.com
finance
2022-10-21 14:36:03

Zerbor Plus Therapeutics (NASDAQ:PSTV) stock was largely flat on Friday after the company's Q3 results which saw Q3 GAAP EPS beat estimates. The cancer drugmaker's GAAP net loss was -$5.2M, or -$0.19 per share, compared to a net loss of -$3.7M, or -$0.28 per share in Q3 2021. In August, Plus said it was getting a three-year, $17.6M grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to fund the company's lead investigational drug Rhenium-186 Nanoliposome (186RNL) to treat patients with leptomeningeal metastases (LM).
